Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 14/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 3/20 | 0.57 |
| ▸ | SRC | P12931 | 3/20 | 0.57 |
| ▸ | BRAF | P15056 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | LTK | P29376 | 1/20 | 0.52 |
| ▸ | TTK | P33981 | 1/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240234 | 0.91 | EGFR (0.70) | HDAC1HDAC3HDAC6EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL2052117 | 0.85 | EGFR (0.71) | EGFRERBB2KDRSRCBRAF | |
| SCHEMBL25249173 | 0.85 | EGFR (0.54) | HDAC1HDAC3HDAC6EGFRERBB2 | |
| SCHEMBL3246208 | 0.84 | EGFR (0.58) | HDAC1HDAC3HDAC6EGFRERBB2 | |
| SCHEMBL5369287 | 0.84 | SRC (0.65) | HDAC1HDAC3HDAC6EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL2052116 | 0.83 | EGFR (0.69) | EGFRERBB2KDRSRCBRAF | |
| SCHEMBL3261578 | 0.82 | EGFR (0.84) | EGFRERBB2KDRSRCLCK | |
| SCHEMBL25270327 | 0.80 | EGFR (0.55) | HDAC1HDAC3HDAC6EGFRKDR | |
| SCHEMBL7233111 | 0.80 | EGFR (0.60) | HDAC1HDAC3HDAC6EGFRERBB2 | |
| SCHEMBL7244628 | 0.80 | EGFR (0.60) | HDAC1HDAC3HDAC6EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1411993-B1 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2010-05-05 | — | — | EP | disclosed |
| EP-1411993-A4 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RES DEV CO (IL) | 2007-08-01 | — | — | EP | disclosed |
| US-7172749-B2 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-02-06 | — | — | US | disclosed |
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| EP-1411993-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002073235-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040265228-A1 | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy | EGFR, ERBB2, TK1 | HDAC1 1546/4885HDAC3 2503/4885HDAC6 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.